The effect of SNPs in CYP450 in chloroquine/primaquine Plasmodium vivax malaria treatment

BACKGROUND: Chloroquine/primaquine is the current therapy to eliminate Plasmodium vivax infection in the Amazon region. AIMS: This study investigates CYP1A2, CYP2C8, CYP2C9, CYP3A4 and CYP3A5 genetic polymorphisms influence on cloroquine/primaquine treatment. PATIENTS & METHODS: Generalized esti...

Descripción completa

Detalles Bibliográficos
Autores principales: Sortica, Vinicius A, Lindenau, Juliana D, Cunha, Maristela G, Ohnishi, Maria DO, Ventura, Ana Maria R, Ribeiro-dos-Santos, Ândrea KC, Santos, Sidney EB, Guimarães, Luciano SP, Hutz, Mara H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7099632/
https://www.ncbi.nlm.nih.gov/pubmed/27767381
http://dx.doi.org/10.2217/pgs-2016-0131
Descripción
Sumario:BACKGROUND: Chloroquine/primaquine is the current therapy to eliminate Plasmodium vivax infection in the Amazon region. AIMS: This study investigates CYP1A2, CYP2C8, CYP2C9, CYP3A4 and CYP3A5 genetic polymorphisms influence on cloroquine/primaquine treatment. PATIENTS & METHODS: Generalized estimating equations analyses were performed to determine the genetic influence in parasitemia and/or gametocytemia clearance over treatment time in 164 patients. RESULTS: An effect of CYP2C8 low-activity alleles on treatment was observed (p = 0.01). From baseline to first day of treatment, wild-type individuals achieved greater reduction of gametocytes than low-activity allele carriers. CYP2C9 and CYP3A5 genes showed a trend for gametocytemia and parasitemia clearance rates. CONCLUSION: Future studies should be performed to access the extent of CYP2C8, CYP2C9 and CYP3A5 gene polymorphisms influence on cloroquine/primaquine treatment.

Ejemplares similares